mitoxantrone ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antineoplastics; anthraquinone derivatives 1821 65271-80-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • mitoxantrone
  • mitoxantrone hydrochloride
  • dihydroxyanthraquinone
  • mitoxanthrone
  • mitozantrone
  • nimitoxantron
  • mitoxantrone dihydrochloride
  • mitoxantrone HCl
An anthracenedione-derived antineoplastic agent.
  • Molecular weight: 444.49
  • Formula: C22H28N4O6
  • CLOGP: 2.24
  • LIPINSKI: 1
  • HAC: 10
  • HDO: 8
  • TPSA: 163.18
  • ALOGS: -2.78
  • ROTB: 12

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 7.50 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 7 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.78 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 0 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 12 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 7.90 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.25 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 53 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 23, 1987 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 325.52 25.24 176 5684 105369 56180838
Acute myeloid leukaemia 246.61 25.24 85 5775 16887 56269320
Myelodysplastic syndrome 159.12 25.24 61 5799 16345 56269862
Pancytopenia 127.00 25.24 91 5769 88624 56197583
Sepsis 119.72 25.24 106 5754 139734 56146473
Second primary malignancy 118.88 25.24 40 5820 7362 56278845
Acute promyelocytic leukaemia 113.89 25.24 25 5835 909 56285298
Neutropenia 102.96 25.24 103 5757 158064 56128143
Leukaemia recurrent 84.66 25.24 21 5839 1307 56284900
Thrombocytopenia 83.64 25.24 86 5774 136138 56150069
Acute myeloid leukaemia recurrent 81.74 25.24 21 5839 1507 56284700
Haemophagocytic lymphohistiocytosis 73.21 25.24 30 5830 9542 56276665
Bone marrow failure 70.05 25.24 41 5819 28245 56257962
Progressive multifocal leukoencephalopathy 69.85 25.24 31 5829 11982 56274225
Acute lymphocytic leukaemia recurrent 64.40 25.24 19 5841 2278 56283929
Bronchopulmonary aspergillosis 63.54 25.24 26 5834 8238 56277969
Febrile bone marrow aplasia 58.57 25.24 23 5837 6549 56279658
Chronic hepatitis 56.81 25.24 14 5846 848 56285359
Strongyloidiasis 52.08 25.24 14 5846 1197 56285010
Congestive cardiomyopathy 50.58 25.24 20 5840 5799 56280408
Lower respiratory tract infection fungal 47.63 25.24 10 5850 293 56285914
Cardiac failure 47.02 25.24 50 5810 82043 56204164
Chloroma 44.67 25.24 9 5851 214 56285993
Streptococcal bacteraemia 44.60 25.24 13 5847 1494 56284713
Mucormycosis 44.56 25.24 15 5845 2759 56283448
Haematotoxicity 43.54 25.24 20 5840 8363 56277844
Product use in unapproved indication 42.26 25.24 62 5798 140760 56145447
Abdominal wall wound 40.24 25.24 7 5853 72 56286135
Multiple organ dysfunction syndrome 39.15 25.24 37 5823 52733 56233474
Cardiomyopathy 38.75 25.24 23 5837 16235 56269972
Hypogammaglobulinaemia 38.69 25.24 17 5843 6409 56279798
Graft versus host disease 37.81 25.24 17 5843 6764 56279443
Venoocclusive liver disease 37.74 25.24 15 5845 4406 56281801
Bone marrow infiltration 36.75 25.24 9 5851 531 56285676
Myeloblast percentage decreased 36.68 25.24 6 5854 41 56286166
Refractory cytopenia with multilineage dysplasia 35.85 25.24 7 5853 141 56286066
Arthralgia 35.69 25.24 5 5855 501664 55784543
B precursor type acute leukaemia 33.31 25.24 7 5853 206 56286001
Aspergillus infection 33.19 25.24 16 5844 7449 56278758
Hepatitis E 32.83 25.24 10 5850 1335 56284872
Respiratory failure 31.65 25.24 44 5816 95018 56191189
Stem cell transplant 30.28 25.24 10 5850 1734 56284473
Stenotrophomonas infection 30.07 25.24 10 5850 1771 56284436
Pain 29.89 25.24 16 5844 663168 55623039
Bacterial sepsis 29.51 25.24 12 5848 3737 56282470
Clostridium bacteraemia 28.22 25.24 6 5854 187 56286020
Diffuse large B-cell lymphoma 28.09 25.24 14 5846 7002 56279205
Cardiotoxicity 26.95 25.24 14 5846 7636 56278571
Leukopenia 26.91 25.24 35 5825 70905 56215302
Neoplasm progression 26.75 25.24 24 5836 31992 56254215
Colitis 26.67 25.24 27 5833 41784 56244423
Differentiation syndrome 26.47 25.24 8 5852 1041 56285166
Streptococcal sepsis 26.24 25.24 9 5851 1751 56284456
Chronic myeloid leukaemia 26.14 25.24 10 5850 2652 56283555
Pyrexia 26.06 25.24 99 5761 418674 55867533
Pulmonary haemorrhage 25.59 25.24 13 5847 6770 56279437
Fatigue 25.33 25.24 27 5833 788525 55497682

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 369.11 22.08 265 6823 121584 31568672
Acute myeloid leukaemia 203.47 22.08 94 6994 18578 31671678
Myelodysplastic syndrome 167.35 22.08 83 7005 19168 31671088
Neutropenia 110.75 22.08 146 6942 140218 31550038
Septic shock 108.33 22.08 101 6987 66057 31624199
Mucormycosis 83.08 22.08 35 7053 5535 31684721
Bone marrow failure 82.05 22.08 60 7028 27948 31662308
Bronchopulmonary aspergillosis 82.02 22.08 46 7042 13588 31676668
Fungal infection 71.36 22.08 43 7045 14508 31675748
Acute lymphocytic leukaemia recurrent 68.41 22.08 26 7062 3144 31687112
Second primary malignancy 63.06 22.08 31 7057 7001 31683255
Leukaemia recurrent 56.83 22.08 19 7069 1583 31688673
Bacteraemia 54.40 22.08 39 7049 17595 31672661
Minimal residual disease 53.05 22.08 13 7075 351 31689905
Ameloblastoma 50.67 22.08 10 7078 94 31690162
Aspiration bone marrow abnormal 49.67 22.08 10 7078 105 31690151
Multiple organ dysfunction syndrome 47.60 22.08 67 7021 68136 31622120
Thrombocytopenia 43.03 22.08 97 6991 142650 31547606
Hypertensive hydrocephalus 41.69 22.08 8 7080 64 31690192
Pneumonia fungal 39.81 22.08 22 7066 6307 31683949
High-grade B-cell lymphoma 39.69 22.08 9 7079 172 31690084
Venoocclusive liver disease 39.19 22.08 23 7065 7389 31682867
Haematopoietic neoplasm 37.30 22.08 7 7081 49 31690207
Neoplasm progression 37.10 22.08 33 7055 20239 31670017
Myelosuppression 37.09 22.08 29 7059 14891 31675365
Cardiotoxicity 35.87 22.08 19 7069 5008 31685248
Mucosal inflammation 35.35 22.08 41 7047 34386 31655870
Abscess fungal 34.74 22.08 8 7080 164 31690092
Aspergillus infection 34.41 22.08 25 7063 11503 31678753
Cytogenetic abnormality 34.18 22.08 11 7077 813 31689443
Neoplasm recurrence 33.92 22.08 14 7074 2100 31688156
Disease progression 33.62 22.08 67 7021 90397 31599859
Clostridium bacteraemia 33.11 22.08 7 7081 95 31690161
Cystitis haemorrhagic 32.21 22.08 18 7070 5271 31684985
Pancytopenia 31.65 22.08 64 7024 87252 31603004
Sepsis 30.90 22.08 89 6999 151840 31538416
Klebsiella infection 30.55 22.08 20 7068 7783 31682473
Febrile bone marrow aplasia 30.45 22.08 20 7068 7826 31682430
Gallbladder adenocarcinoma 30.10 22.08 5 7083 15 31690241
Refractory anaemia with an excess of blasts 27.56 22.08 8 7080 417 31689839
Neutropenic colitis 27.56 22.08 13 7075 2679 31687577
Respiratory tract infection fungal 27.43 22.08 9 7079 707 31689549
Product use in unapproved indication 27.21 22.08 65 7023 99106 31591150
Acute lymphocytic leukaemia 27.15 22.08 14 7074 3492 31686764
Genotoxicity 26.52 22.08 5 7083 36 31690220
Enamel anomaly 26.25 22.08 6 7082 119 31690137
Encephalopathy 25.80 22.08 34 7054 32440 31657816
Klebsiella sepsis 25.48 22.08 11 7077 1844 31688412
Progressive multifocal leukoencephalopathy 25.29 22.08 19 7069 9194 31681062
Acute myeloid leukaemia recurrent 24.82 22.08 11 7077 1963 31688293
Osteonecrosis 24.21 22.08 22 7066 13862 31676394
Hyperammonaemic encephalopathy 23.56 22.08 11 7077 2215 31688041
Colitis 23.18 22.08 33 7055 33854 31656402
Large granular lymphocytosis 23.04 22.08 6 7082 208 31690048
Fungaemia 22.90 22.08 11 7077 2358 31687898
Differentiation syndrome 22.64 22.08 9 7079 1226 31689030
Drug resistance 22.52 22.08 27 7061 23426 31666830
Cholangitis infective 22.33 22.08 6 7082 235 31690021

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 564.47 20.79 370 11014 203948 70713112
Acute myeloid leukaemia 429.73 20.79 168 11216 30772 70886288
Myelodysplastic syndrome 318.18 20.79 134 11250 29651 70887409
Neutropenia 184.12 20.79 216 11168 256940 70660120
Second primary malignancy 174.43 20.79 69 11315 12982 70904078
Bone marrow failure 149.88 20.79 95 11289 48915 70868145
Leukaemia recurrent 122.63 20.79 36 11348 2739 70914321
Sepsis 119.20 20.79 170 11214 244375 70672685
Acute lymphocytic leukaemia recurrent 117.99 20.79 40 11344 4864 70912196
Septic shock 112.89 20.79 113 11271 112145 70804915
Thrombocytopenia 108.91 20.79 161 11223 238949 70678111
Bronchopulmonary aspergillosis 102.06 20.79 55 11329 20947 70896113
Acute promyelocytic leukaemia 100.67 20.79 27 11357 1475 70915585
Pancytopenia 96.53 20.79 120 11264 150987 70766073
Mucormycosis 95.41 20.79 39 11345 7975 70909085
Acute myeloid leukaemia recurrent 85.79 20.79 28 11356 3026 70914034
Venoocclusive liver disease 81.53 20.79 38 11346 10640 70906420
Multiple organ dysfunction syndrome 77.12 20.79 91 11293 108424 70808636
Progressive multifocal leukoencephalopathy 76.11 20.79 44 11340 19170 70897890
Bacteraemia 70.62 20.79 49 11335 29260 70887800
Fungal infection 68.45 20.79 53 11331 37414 70879646
Product use in unapproved indication 62.37 20.79 116 11268 207362 70709698
Febrile bone marrow aplasia 59.92 20.79 32 11352 11959 70905101
Clostridium bacteraemia 59.45 20.79 13 11371 296 70916764
Ameloblastoma 53.98 20.79 10 11374 94 70916966
Neoplasm recurrence 53.20 20.79 21 11363 3920 70913140
Aspergillus infection 52.99 20.79 34 11350 17834 70899226
Haemophagocytic lymphohistiocytosis 52.50 20.79 35 11349 19577 70897483
Cytogenetic abnormality 52.37 20.79 15 11369 1045 70916015
Lower respiratory tract infection fungal 50.53 20.79 14 11370 864 70916196
Refractory anaemia with an excess of blasts 50.22 20.79 14 11370 884 70916176
Chronic hepatitis 49.28 20.79 15 11369 1291 70915769
Acute lymphocytic leukaemia 46.29 20.79 21 11363 5524 70911536
Neoplasm progression 46.26 20.79 46 11338 45182 70871878
Respiratory failure 45.34 20.79 90 11294 168645 70748415
Cardiomyopathy 45.34 20.79 36 11348 26337 70890723
Differentiation syndrome 45.05 20.79 16 11368 2231 70914829
Drug resistance 45.02 20.79 42 11342 38148 70878912
Cardiotoxicity 42.90 20.79 25 11359 11045 70906015
Fungaemia 42.31 20.79 18 11366 4064 70912996
Klebsiella sepsis 41.45 20.79 16 11368 2815 70914245
High-grade B-cell lymphoma 40.75 20.79 9 11375 215 70916845
Staphylococcal infection 39.92 20.79 46 11338 53358 70863702
Myelosuppression 39.14 20.79 35 11349 30110 70886950
Fatigue 39.11 20.79 45 11339 824274 70092786
Enterococcal infection 38.97 20.79 26 11358 14556 70902504
Stenotrophomonas infection 38.84 20.79 16 11368 3333 70913727
Aplastic anaemia 38.05 20.79 27 11357 16689 70900371
Haematotoxicity 38.04 20.79 25 11359 13649 70903411
Stem cell transplant 37.79 20.79 16 11368 3569 70913491
Arthralgia 37.48 20.79 17 11367 503373 70413687
Disease progression 36.71 20.79 79 11305 156593 70760467
Colitis 36.45 20.79 48 11336 63766 70853294
Malignant neoplasm progression 36.45 20.79 68 11316 121671 70795389
Abdominal wall wound 36.30 20.79 7 11377 83 70916977
Haematopoietic neoplasm 36.00 20.79 7 11377 87 70916973
Cardiac failure 35.50 20.79 74 11310 143467 70773593
Neutropenic colitis 35.35 20.79 17 11367 5097 70911963
Cystitis haemorrhagic 34.88 20.79 20 11364 8573 70908487
Pain 34.75 20.79 30 11354 628786 70288274
Pneumonia fungal 34.71 20.79 21 11363 9932 70907128
Klebsiella infection 34.66 20.79 24 11360 14268 70902792
Hyperammonaemic encephalopathy 34.50 20.79 16 11368 4427 70912633
Hypogammaglobulinaemia 34.32 20.79 22 11362 11516 70905544
Respiratory tract infection fungal 34.13 20.79 11 11373 1142 70915918
Myeloblast percentage decreased 34.08 20.79 6 11378 41 70917019
Chloroma 34.08 20.79 10 11374 759 70916301
Refractory cytopenia with multilineage dysplasia 33.73 20.79 8 11376 264 70916796
Graft versus host disease 33.58 20.79 24 11360 14999 70902061
Candida infection 33.30 20.79 34 11350 34439 70882621
Hypertensive hydrocephalus 33.20 20.79 5 11379 10 70917050
Stomatococcal infection 33.20 20.79 8 11376 283 70916777
Bone marrow infiltration 32.94 20.79 9 11375 527 70916533
Chronic lymphocytic leukaemia recurrent 31.72 20.79 9 11375 606 70916454
Diffuse large B-cell lymphoma recurrent 31.68 20.79 14 11370 3462 70913598
Hepatic failure 30.85 20.79 42 11342 57583 70859477
Pyrexia 30.76 20.79 184 11200 606768 70310292
Strongyloidiasis 30.76 20.79 14 11370 3709 70913351
Pruritus 30.19 20.79 9 11375 345551 70571509
Fall 30.04 20.79 17 11367 444079 70472981
Mucosal inflammation 29.79 20.79 45 11339 67805 70849255
Chronic myeloid leukaemia 29.15 20.79 14 11370 4187 70912873
Drug hypersensitivity 28.77 20.79 4 11380 262455 70654605
Abscess fungal 28.77 20.79 7 11377 258 70916802
Encephalopathy 28.65 20.79 42 11342 61619 70855441
Pulmonary haemorrhage 28.64 20.79 21 11363 13652 70903408
Osteonecrosis 28.60 20.79 29 11355 29131 70887929
Nausea 28.43 20.79 59 11325 852029 70065031
Acute febrile neutrophilic dermatosis 28.34 20.79 13 11371 3506 70913554
Hepatitis B 27.99 20.79 17 11367 8097 70908963
Aspiration bone marrow abnormal 27.26 20.79 6 11378 141 70916919
Disseminated intravascular coagulation 26.91 20.79 30 11354 33568 70883492
Pseudomonas infection 26.55 20.79 23 11361 18971 70898089
Streptococcal bacteraemia 26.50 20.79 12 11372 3141 70913919
Lymphopenia 26.45 20.79 27 11357 27332 70889728
Leukopenia 26.41 20.79 55 11329 106505 70810555
Pain in extremity 26.13 20.79 10 11374 328072 70588988
Blood culture positive 25.79 20.79 16 11368 7910 70909150
Dizziness 25.78 20.79 22 11362 464119 70452941
Minimal residual disease 25.57 20.79 7 11377 413 70916647
Nasopharyngitis 25.28 20.79 3 11381 222203 70694857
Hepatitis E 25.06 20.79 11 11373 2677 70914383
Escherichia bacteraemia 24.73 20.79 14 11370 5855 70911205
Chromosome analysis abnormal 24.58 20.79 6 11378 224 70916836
Portal hypertension 23.42 20.79 14 11370 6478 70910582
Cytomegalovirus infection 22.84 20.79 30 11354 39728 70877332
Acute myelomonocytic leukaemia 22.81 20.79 6 11378 304 70916756
Pseudomonal sepsis 22.77 20.79 13 11371 5524 70911536
Streptococcal sepsis 22.74 20.79 10 11374 2444 70914616
Graft versus host disease in gastrointestinal tract 21.92 20.79 13 11371 5931 70911129
Cerebral fungal infection 21.88 20.79 6 11378 356 70916704
Leukaemic infiltration 21.84 20.79 5 11379 141 70916919
Large granular lymphocytosis 21.79 20.79 6 11378 362 70916698
Weight increased 21.73 20.79 6 11378 242325 70674735
Metastasis 21.58 20.79 13 11371 6101 70910959
Bacterial sepsis 21.31 20.79 14 11370 7633 70909427
Primary hypogonadism 20.88 20.79 5 11379 172 70916888

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01DB07 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES
Anthracyclines and related substances
FDA MoA N0000000176 Topoisomerase Inhibitors
MeSH PA D000700 Analgesics
MeSH PA D000970 Antineoplastic Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D018689 Sensory System Agents
MeSH PA D059005 Topoisomerase II Inhibitors
FDA EPC N0000175609 Topoisomerase Inhibitor
CHEBI has role CHEBI:23240 chromophores
CHEBI has role CHEBI:37958 dyes
CHEBI has role CHEBI:76924 plant metabolites
CHEBI has role CHEBI:35610 antineoplastic agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Acute myeloid leukemia, disease indication 91861009
Relapsing remitting multiple sclerosis indication 426373005 DOID:2378
Metastatic Prostate Carcinoma indication
Follicular non-Hodgkin's lymphoma off-label use 308121000
Metastatic Breast Carcinoma off-label use
Progressive Diffuse Large B-Cell Lymphoma off-label use
Mycosis contraindication 3218000 DOID:1564
Viral disease contraindication 34014006 DOID:934
Chronic heart failure contraindication 48447003
Hepatic failure contraindication 59927004
Acute infectious disease contraindication 63171007
Leukopenia contraindication 84828003 DOID:615
Left heart failure contraindication 85232009
Bacterial infectious disease contraindication 87628006
Radiation oncology AND/OR radiotherapy contraindication 108290001
Acute disease of cardiovascular system contraindication 128487001
Seizure disorder contraindication 128613002
Disease of liver contraindication 235856003 DOID:409
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Bone marrow depression contraindication 307762000
Breastfeeding (mother) contraindication 413712001




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.37 acidic
pKa2 10.7 acidic
pKa3 9.13 Basic
pKa4 8.52 Basic
pKa5 4.01 Basic
pKa6 1.49 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
DNA topoisomerase 2-alpha Enzyme INHIBITOR IC90 5.96 WOMBAT-PK CHEMBL
Potassium voltage-gated channel subfamily H member 2 Ion channel Ki 5.53 DRUG MATRIX
Multidrug resistance protein 1 Transporter IC50 5.84 WOMBAT-PK
Sodium-dependent noradrenaline transporter Transporter Ki 5.31 DRUG MATRIX
5-hydroxytryptamine receptor 2C GPCR Ki 5.73 DRUG MATRIX
Muscarinic acetylcholine receptor M1 GPCR Ki 6.74 DRUG MATRIX
Muscarinic acetylcholine receptor M2 GPCR Ki 7.11 DRUG MATRIX
Muscarinic acetylcholine receptor M4 GPCR Ki 7.05 DRUG MATRIX
Canalicular multispecific organic anion transporter 1 Transporter WOMBAT-PK
Multidrug resistance-associated protein 1 Transporter IC50 6.29 WOMBAT-PK
ATP-binding cassette sub-family G member 2 Transporter Kact 5.16 WOMBAT-PK
Tyrosine-protein kinase Fyn Kinase IC50 5.90 DRUG MATRIX
Receptor tyrosine-protein kinase erbB-2 Kinase IC50 5.69 DRUG MATRIX
Serine/threonine-protein kinase pim-1 Kinase IC50 7.29 CHEMBL
Solute carrier family 22 member 1 Transporter IC50 4.36 CHEMBL
DNA-(apurinic or apyrimidinic site) lyase Enzyme IC50 5.70 CHEMBL
Tyrosine-protein kinase BTK Kinase IC50 6 CHEMBL
Proto-oncogene tyrosine-protein kinase ROS Kinase IC50 5.52 CHEMBL
Solute carrier family 22 member 2 Transporter IC50 4.13 CHEMBL
Multidrug and toxin extrusion protein 1 Transporter IC50 6.72 CHEMBL
Multidrug and toxin extrusion protein 2 Transporter IC50 6.28 CHEMBL
Solute carrier family 22 member 3 Transporter IC50 4.22 CHEMBL
DNA-3-methyladenine glycosylase Enzyme IC50 5.60 CHEMBL
Epidermal growth factor receptor Kinase IC50 5.27 DRUG MATRIX
TAR DNA-binding protein 43 Unclassified IC50 5 CHEMBL
Arachidonate 15-lipoxygenase Enzyme IC50 5.75 DRUG MATRIX
Integrase Enzyme IC50 5.42 CHEMBL
Dual specificity tyrosine-phosphorylation-regulated kinase 1A Kinase AC50 5.02 CHEMBL

External reference:

IDSource
4019842 VUID
N0000147929 NUI
D02166 KEGG_DRUG
70476-82-3 SECONDARY_CAS_RN
4019527 VANDF
4019842 VANDF
C0026259 UMLSCUI
CHEBI:50729 CHEBI
MIX PDB_CHEM_ID
CHEMBL58 ChEMBL_ID
CHEMBL1417019 ChEMBL_ID
CHEMBL1200827 ChEMBL_ID
D008942 MESH_DESCRIPTOR_UI
DB01204 DRUGBANK_ID
7242 IUPHAR_LIGAND_ID
4922 INN_ID
BZ114NVM5P UNII
4212 PUBCHEM_CID
203129 RXNORM
5124 MMSL
81184 MMSL
d00306 MMSL
002676 NDDF
004828 NDDF
108791001 SNOMEDCT_US
386913001 SNOMEDCT_US
412249002 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
mitoXANTRONE HUMAN PRESCRIPTION DRUG LABEL 1 0703-4680 INJECTION, SOLUTION, CONCENTRATE 2 mg INTRAVENOUS ANDA 24 sections
mitoXANTRONE HUMAN PRESCRIPTION DRUG LABEL 1 0703-4680 INJECTION, SOLUTION, CONCENTRATE 2 mg INTRAVENOUS ANDA 24 sections
mitoXANTRONE HUMAN PRESCRIPTION DRUG LABEL 1 0703-4685 INJECTION, SOLUTION, CONCENTRATE 2 mg INTRAVENOUS ANDA 24 sections
mitoXANTRONE HUMAN PRESCRIPTION DRUG LABEL 1 0703-4685 INJECTION, SOLUTION, CONCENTRATE 2 mg INTRAVENOUS ANDA 24 sections
mitoXANTRONE HUMAN PRESCRIPTION DRUG LABEL 1 0703-4686 INJECTION, SOLUTION, CONCENTRATE 2 mg INTRAVENOUS ANDA 24 sections
mitoXANTRONE HUMAN PRESCRIPTION DRUG LABEL 1 0703-4686 INJECTION, SOLUTION, CONCENTRATE 2 mg INTRAVENOUS ANDA 24 sections
Mitoxantrone HUMAN PRESCRIPTION DRUG LABEL 1 61703-343 INJECTION, SOLUTION, CONCENTRATE 2 mg INTRAVENOUS ANDA 28 sections
Mitoxantrone HUMAN PRESCRIPTION DRUG LABEL 1 61703-343 INJECTION, SOLUTION, CONCENTRATE 2 mg INTRAVENOUS ANDA 28 sections
Mitoxantrone HUMAN PRESCRIPTION DRUG LABEL 1 63323-132 INJECTION, SOLUTION 2 mg INTRAVENOUS ANDA 15 sections